Emerging Role of Organ‐on‐a‐Chip Technologies in Quantitative Clinical Pharmacology Evaluation
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The recently enacted Prescription Drug User Fee Act (PDUFA) VI includes in its performance goals “enhancing regulatory science and expediting drug development.” The key elements in “enhancing regulatory decision tools to support drug development and review” include “advancing model‐informed drug development (MIDD).” This paper describes (i) the US Food and Drug Administration (FDA) Office of Clinical Pharmacology's continuing efforts in developing quantitative clinical pharmacology models (disease, drug, and clinical trial models) to advance MIDD, (ii) how emerging novel tools, such as organ‐on‐a‐chip technologies or microphysiological systems, can provide new insights into physiology and disease mechanisms, biomarker identification and evaluation, and elucidation of mechanisms of adverse drug reactions, and (iii) how the single organ or linked organ microphysiological systems can provide critical system parameters for improved physiologically‐based pharmacokinetic and pharmacodynamic evaluations. Continuous public‐private partnerships are critical to advance this field and in the application of these new technologies in drug development and regulatory review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kim, H. J., Huh, D., Hamilton, G., & Ingber, D. E. (2012) · Lab on a Chip · doi:10.1039/c2lc40074j · Cited by 1,734
Wang, G., McCain, M. L., Yang, L., He, A., Pasqualini, F. S., Agarwal, A., Yuan, H., Jiang, D., Zhang, D., Zangi, L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3545 · Cited by 837 · cited 1×
“The authors further demonstrated with Cas9mediated genome editing that mutation in the gene encoding tafazzin was sufficient to cause the disease phenotype.(35) The use of patient- derived cells opens the potential for personalized disease modeling as well as the ability to model the longitudinal progression of the di…”
BackgroundInterconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies
Edington, C. D., Chen, W. L. K., Geishecker, E., Kassis, T., Soenksen, L. R., Bhushan, B. M., Freake, D., Kirschner, J., Maass, C., Tsamandouras, N., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22749-0 · Cited by 487
Benam, K. H., Novak, R., Nawroth, J., Hirano-Kobayashi, M., Ferrante, T. C., Choe, Y., Prantil-Baun, R., Weaver, J. C., Bahinski, A., Parker, K. K., et al. (2016) · Cell Systems · doi:10.1016/j.cels.2016.10.003 · Cited by 309
The utility of modeling and simulation in drug development and regulatory review
Huang, S.-M., Abernethy, D. R., Wang, Y., Zhao, P., & Zineh, I. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23570 · Cited by 206
Self-citationGao, D., Liu, H., Lin, J.-M., Wang, Y., & Jiang, Y. (2013) · Lab on a Chip · doi:10.1039/c2lc41215b · Cited by 135
Metabolic Patterning on a Chip: Towards in vitro Liver Zonation of Primary Rat and Human Hepatocytes
Kang, Y. B., Eo, J., Mert, S., Yarmush, M. L., & Usta, O. B. (2018) · Scientific Reports · doi:10.1038/s41598-018-27179-6 · Cited by 122
Fabre, K. M., Livingston, C., & Tagle, D. A. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214538916 · Cited by 82
Scotcher, D., Jones, C., Rostami-Hodjegan, A., & Galetin, A. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.03.018 · Cited by 61
Development of a Dynamic Physiologically Based Mechanistic Kidney Model to Predict Renal Clearance
Huang, W., & Isoherranen, N. (2018) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12321 · Cited by 49 · cited 1×
“Passive permeability measures from Caco2 or Manine- Darby canine kidney (MDCK) cells are generally used to estimate and predict reabsorption clearance in the kidneys and can be used to populate PBPK models.(61,62) This approach has many weaknesses, and, therefore, better in vitro models that closely mimic the processe…”
MethodSelf-citation
Cited by
Human biomimetic liver microphysiology systems in drug development and precision medicine
Gough, A., Soto-Gutierrez, A., Vernetti, L., Ebrahimkhani, M. R., Stern, A. M., & Taylor, D. L. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00386-1 · Cited by 117
Development of a Dynamic Physiologically Based Mechanistic Kidney Model to Predict Renal Clearance
Huang, W., & Isoherranen, N. (2018) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12321 · Cited by 49
Self-citationTomlinson, L., Ramsden, D., Leite, S. B., Beken, S., Bonzo, J. A., Brown, P., Candarlioglu, P. L., Chan, T. S., Chen, E., Choi, C. K., et al. (2024) · Advanced Biology · doi:10.1002/adbi.202300131 · Cited by 33
Metadata
- Authors
- Isoherranen, N., Madabushi, R., & Huang, S.
- Venue
- Clinical and Translational Science
- Publisher
- Wiley
- Published
- 2019-03
- Volume
- 12
- Issue
- 2
- Pages
- 113-121
- ISSN
- 1752-8054 (ISSN-L)
- 1752-8062
- OpenAlex
- W2913340122
- Cited by
- 50
- References
- 10
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging Role of Organ‐on‐a‐Chip Technologies in Quantitative Clinical Pharmacology Evaluation. https://app.cochat.ai/papers/10.1111/cts.12627
- The paper
- Isoherranen, N., Madabushi, R., & Huang, S. (2019). Emerging Role of Organ‐on‐a‐Chip Technologies in Quantitative Clinical Pharmacology Evaluation. Clinical and Translational Science. https://doi.org/10.1111/cts.12627
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.